Fennec Pharmaceuticals/$FENC
1D1W1MYTD1Y5YMAX
Capital at risk
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
- Ticker
- $FENC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 35
- Headquarters
- Research Triangle Park, United States
- Website
- www.fennecpharma.com
FENC Metrics
BasicAdvanced
$372M
-
-$0.10
1.07
-
Price and volume
Market cap
$372M
Beta
1.07
52-week high
$13.25
52-week low
$5.65
Average daily volume
260K
Financial strength
Current ratio
5.85
Quick ratio
5.205
Interest coverage (TTM)
-1.19%
Profitability
EBITDA (TTM)
-1.02
Gross margin (TTM)
93.73%
Net profit margin (TTM)
-5.49%
Operating margin (TTM)
-1.90%
Effective tax rate (TTM)
-4.77%
Revenue per employee (TTM)
$1,690,000
Management effectiveness
Return on assets (TTM)
-1.16%
Return on equity (TTM)
-18.58%
Valuation
Price to revenue (TTM)
5.75
Price to book
8.77
Price to tangible book (TTM)
8.77
Price to free cash flow (TTM)
-166.926
Free cash flow yield (TTM)
-0.60%
Free cash flow per share (TTM)
-0.064
Growth
Revenue change (TTM)
77.83%
Earnings per share change (TTM)
-77.26%
3-year revenue growth (CAGR)
108.46%
3-year earnings per share growth (CAGR)
-53.35%
10-year earnings per share growth (CAGR)
-4.55%
Bulls say / Bears say
Fennec reported Q1 2026 net product sales of $15.1 million, up 73% year-over-year, driven by increased PEDMARK adoption across key tumor types. (Thomson Reuters)
Under the Norgine licensing agreement, Fennec received approximately $43 million upfront and may earn up to $230 million in additional milestone payments plus tiered royalties, providing significant non-dilutive funding and future revenue potential. (SEC 10-Q)
Fennec has initiated multiple investigator-sponsored studies—including a real-world study and a Phase I/II trial—to evaluate PEDMARK in adolescent, young adult, and adult populations, broadening its potential label and market. (SEC 10-Q)
The company operates as a single reporting segment solely focused on PEDMARK commercialization, exposing revenue to concentrated product risk if market adoption slows. (SEC 10-Q)
Selling and marketing expenses surged to $10.7 million in Q2 2026 from $4.8 million a year earlier, indicating rising commercialization costs that may pressure margins if sales growth decelerates. (GlobeNewswire)
Fennec estimates a U.S. pediatric cisplatin-treated target population of only approximately 2,157 patients annually (out of 11,400 total pediatric solid tumor cases), suggesting a limited market ceiling. (SEC 10-K)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Upcoming events
No upcoming events
FENC News
AllArticlesVideos
Funds containing FENC
Fund name | Fund size | $FENC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.